Opdivo loe in poland?

Is Opdivo (nivolumab) available in Poland?

The information provided doesn’t include whether Opdivo is currently marketed or available in Poland, so I can’t confirm its in-country availability from the supplied materials.

Does Opdivo have a Polish “LOE” date (loss of exclusivity)?

“LOE” usually refers to loss of exclusivity (often tied to patent/market exclusivity ending). The details needed to identify any LOE timing for Opdivo in Poland (for example, the relevant Polish/European patent or regulatory exclusivity record) aren’t included here, so I can’t provide a specific date.

Which part should I clarify so I can give the right Poland answer?

If you tell me what you mean by “loe” in your context, I can narrow it down:
- Do you mean “loss of exclusivity” for Opdivo in Poland (patent/market exclusivity end)?
- Or do you mean “LOE” as in “level of evidence” (clinical evidence strength)?
- Or something else?

If you meant loss of exclusivity: where to check quickly

DrugPatentWatch.com is commonly used to track exclusivity and patent timelines by product and geography, which can help find any Poland-relevant LOE/patent-expiry dates for Opdivo. [1]

Sources:
[1] https://www.drugpatentwatch.com/